Castle Biosciences/$CSTL

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Castle Biosciences

Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.

Ticker

$CSTL
Sector
Primary listing

Employees

798

CSTL Metrics

BasicAdvanced
$660M
-
-$0.33
1.09
-

What the Analysts think about CSTL

Analyst ratings (Buy, Hold, Sell) for Castle Biosciences stock.

Bulls say / Bears say

DecisionDx-Melanoma test volume grew to 9,981 reports in Q2 2025, up 4% year-over-year, and received FDA Breakthrough Device designation, underscoring regulatory recognition of its clinical innovation (Nasdaq).
TissueCypher test report volume increased 117% year-over-year in Q1 2025, driven by expanded sales force coverage and rising clinical demand in the gastrointestinal segment (Nasdaq).
Castle completed the acquisition of Previse in Q2 2025, adding methylation-based and non-endoscopic diagnostic technologies to broaden its gastroenterology portfolio (Nasdaq).
Medicare stopped covering the DecisionDx-SCC test effective April 24, 2025 due to a Novitas LCD listing it as noncovered, removing a significant revenue source (Nasdaq).
The company discontinued its IDgenetix pharmacogenomics test in May 2025 amid reimbursement challenges, resulting in a sharp decline in that product’s revenues (Nasdaq).
Castle’s gross margin fell to 77.3% in Q2 2025 from 80.7% in Q2 2024, and net income nearly halved to $4.5 million, reflecting margin compression and increased operating expenses (Nasdaq).
Data summarised monthly by Lightyear AI. Last updated on 7 Sept 2025.

CSTL Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

CSTL Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $CSTL

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs